Ann Lab Med.  2025 Mar;45(2):223-227. 10.3343/alm.2024.0369.

Clinical Outcomes and Molecular Characteristics of Bacteroides fragilis Infections

• Kim B
• Kim M
• Lee K
• Lee Y

• KMID: 2565654
• DOI: http://doi.org/10.3343/alm.2024.0369

Abstract

Bacteroides fragilis is the most common opportunistic anaerobic pathogen. In the absence of appropriate antimicrobial therapy, mortality rates associated with B. fragilis group infections can reach as high as 50%. Therefore, we aimed to elucidate the clinical characteristics and outcomes of B. fragilis infections and the molecular genetic characteristics of B. fragilis isolates. Forty B. fragilis clinical isolates were collected at Hanyang University Hospital between January 2022 and December 2023. Antimicrobial susceptibility was tested using the agar dilution method. Whole-genome sequencing was conducted using the Illumina platform (Illumina, San Diego, CA, USA). Various multilocus sequence types of B. fragilis were identified, including ST149 (N = 4), ST11 (N = 4), ST1 (N = 3), ST21 (N = 2), and ST157 (N = 1). The insertion sequence (IS) IS1187, located upstream of cfiA, was associated with high-level carbapenem resistance in the ST157 isolate. B. fragilis toxin genes (bft) were identified in 30% of isolates. The most common comorbidities were diabetes mellitus (26.5%) and non-metastatic cancer (23.5%). Five patients (14.7%) died within 30 days, and two (5.9%) deaths were directly attributable to B. fragilis infection. The emergence of high-level MIC carbapenem-resistant B. fragilis ST157 has led to caution in the presence of B. fragilis infections.

Keyword

Bacteremia; Bacteroides fragilis; cfiA; Intraabdominal infection; ST157

Reference

References

1. Jean S, Wallace MJ, Dantas G, Burnham CD. 2022; Time for some group therapy: update on identification, antimicrobial resistance, taxonomy, and clinical significance of the Bacteroides fragilis group. J Clin Microbiol. 60:e0236120. DOI: 10.1128/jcm.02361-20. PMID: 35700139. PMCID: PMC9491163.

2. Cheng CW, Lin HS, Ye JJ, Yang CC, Chiang PC, Wu TS, et al. 2009; Clinical significance of and outcomes for Bacteroides fragilis bacteremia. J Microbiol Immunol Infect. 42:243–50.

3. Byun JH, Kim M, Lee Y, Lee K, Chong Y. 2019; Antimicrobial susceptibility patterns of anaerobic bacterial clinical isolates from 2014 to 2016, including recently named or renamed species. Ann Lab Med. 39:190–9. DOI: 10.3343/alm.2019.39.2.190. PMID: 30430782. PMCID: PMC6240532.

4. Fang H, Li X, Yan MK, Tong MK, Chow KH, Cheng VC, et al. 2023; Antimicrobial susceptibility of Bacteroides fragilis group organisms in Hong Kong, 2020-2021. Anaerobe. 82:102756. DOI: 10.1016/j.anaerobe.2023.102756. PMID: 37429411.

5. Wallace MJ, Jean S, Wallace MA, Burnham CD, Dantas G. 2022; Comparative genomics of Bacteroides fragilis group isolates reveals species-dependent resistance mechanisms and validates clinical tools for resistance prediction. mBio. 13:e0360321. DOI: 10.1128/mbio.03603-21. PMID: 35038926. PMCID: PMC8764542. PMID: 9be79e0ed77548e5bfff602cfecd8f92.

6. Gao Q, Wu S, Xu T, Zhao X, Huang H, Hu F. 2019; Emergence of carbapenem resistance in Bacteroides fragilis in China. Int J Antimicrob Agents. 53:859–63. DOI: 10.1016/j.ijantimicag.2019.02.017. PMID: 30831235.

7. Yekani M, Baghi HB, Naghili B, Vahed SZ, Sóki J, Memar MY. 2020; To resist and persist: important factors in the pathogenesis of Bacteroides fragilis. Microb Pathog. 149:104506. DOI: 10.1016/j.micpath.2020.104506. PMID: 32950639.

8. Garrett WS. 2019; The gut microbiota and colon cancer. Science. 364:1133–5. DOI: 10.1126/science.aaw2367. PMID: 31221845.

9. Charlson ME, Pompei P, Ales KL, MacKenzie CR. 1987; A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 40:373–83. DOI: 10.1016/0021-9681(87)90171-8. PMID: 3558716.

10. Rhee JY, Kwon KT, Ki HK, Shin SY, Jung DS, Chung DR, et al. 2009; Scoring systems for prediction of mortality in patients with intensive care unit-acquired sepsis: a comparison of the Pitt bacteremia score and the Acute Physiology and Chronic Health Evaluation II scoring systems. Shock. 31:146–50. DOI: 10.1097/SHK.0b013e318182f98f. PMID: 18636041.

11. CDC/NHSN Surveillance definitions for specific types of infections. https://www.cdc.gov/nhsn/pdfs/pscmanual/17pscnosinfdef_current.pdf. Updated on Jan 2024.

12. CLSI. 2012. Methods for antimicrobial susceptibility testing of anaerobic bacteria. 8th ed. Clinical and Laboratory Standards Institute;Wayne, PA: M11-A8. DOI: 10.1016/j.anaerobe.2021.102417.

13. CLSI. 2023. Performance standards for antimicrobial susceptibility testing. 33rd ed. Clinical and Laboratory Standards Institute;Wayne, PA: M100. DOI: 10.1016/s0196-4399(01)88009-0.

14. Yim J, Lee Y, Kim M, Seo YH, Kim WH, Yong D, et al. 2015; Antimicrobial susceptibility of clinical isolates of Bacteroides fragilis group organisms recovered from 2009 to 2012 in a Korean hospital. Ann Lab Med. 35:94–8. DOI: 10.3343/alm.2015.35.1.94. PMID: 25553287. PMCID: PMC4272972.

15. Kawamoto Y, Kosai K, Ota K, Uno N, Sakamoto K, Hasegawa H, et al. 2021; Rapid detection and surveillance of cfiA-positive Bacteroides fragilis using matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Anaerobe. 72:102448. DOI: 10.1016/j.anaerobe.2021.102448. PMID: 34537378.

16. Jeverica S, Sóki J, Premru MM, Nagy E, Papst L. 2019; High prevalence of division II (cfiA positive) isolates among blood stream Bacteroides fragilis in Slovenia as determined by MALDI-TOF MS. Anaerobe. 58:30–4. DOI: 10.1016/j.anaerobe.2019.01.011. PMID: 30716401.

17. Nielsen FD, Skov MN, Sydenham TV, Justesen US. 2023; Development and clinical application of a multilocus sequence typing scheme for Bacteroides fragilis based on whole-genome sequencing data. Microbiol Spectr. 11:e0511122. DOI: 10.1128/spectrum.05111-22. PMID: 36943061. PMCID: PMC10101032.